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OPIOID CONSUMPTION IN FEMALES 3 
 4 
Abstract 5 
Introduction:  This study examined whether a modern TKA protocol without a tourniquet 6 
results in less patient-reported pain and in-hospital opioid consumption compared to TKA with a 7 
tourniquet. 8 
Methods: A retrospective study of 203 primary unilateral cemented TKAs consecutively 9 
performed with or without tourniquet was performed.  Identical perioperative pain and blood loss 10 
protocols were used in all cases.  In tourniquetless TKAs, the tourniquet was not inflated at any 11 
time and sterile CO2 gas compression maximized cement interdigitation.   12 
Results:  After exclusions for scientific confounds, 184 TKAs (93 with tourniquet; 91 13 
tourniquetless) were analyzed.  Controlling for multiple covariates, females with a tourniquet 14 
reported significantly more pain (p = 0.002) and opioid consumption (p < 0.001) the first 24 15 
hours following surgery compared to females without a tourniquet.  There were no differences in 16 
pain (p = 0.192) or amount of opioids consumed (p = 0.203) among males with and without a 17 
tourniquet. Tourniquet use resulted in a significant reduction in blood loss for both females (p ≤ 18 
0.040) and males (p ≤ 0.020), although the total blood savings of approximately 200 milliliters is 19 
of unknown clinical significance. 20 
Conclusion:  Avoiding tourniquet use during TKA for females may be a relatively risk-free 21 
adjunct to minimize opioid consumption during hospitalization.  Further study is warranted to 22 
elucidate the factors accounting for different outcomes in females and males. 23 
Keywords: total knee arthroplasty, tourniquet, tourniquetless, pain, opioids, blood loss 24 
  25 
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Introduction 26 
Pneumatic tourniquets are commonly used in total knee arthroplasty (TKA) to reduce 27 
intraoperative blood loss, enhance operative visualization, provide a cleaner field for cement 28 
penetration and fixation, and increase operative efficiency.  The use of tourniquets during TKA 29 
has been a subject of debate in the scientific literature due to risks and benefits associated with 30 
their use.  Systematic reviews and meta-analyses of randomized controlled trials (RCTs) show 31 
high similarity in results.  Pooled analyses of 634 knees, [1] 493 patients, [2] 859 patients, [3] 32 
and 689 knees [4] all showed significantly less intraoperative blood loss in tourniquet groups, 33 
although two of these studies showed no difference in calculated (“true” or “actual”) blood loss. 34 
[1, 4]  Three of these reviews reported no statistically significant differences in the incidence of 35 
deep vein thrombosis and/or pulmonary embolism, [1-3] although two reviews [1, 4] showed a 36 
greater likelihood of thrombotic events in general in tourniquet groups.  Wound problems, [1] 37 
minor complications, [2] and surgical site infection [3] were all more likely when a tourniquet 38 
was used.  Two systematic reviews and meta-analyses of RCTs comparing tourniquet release 39 
before and after wound closure comprised of 670 knees [5] and 1170 patients [6] reported that 40 
complications were lower when tourniquets were released prior to wound closure.  Further, 41 
several studies have demonstrated that tourniquets result in greater pain in the immediate 42 
postoperative period after TKA.[7-12]   Some studies additionally have noted either an increase 43 
[7, 12] or no difference in [11] analgesia consumption in relation to this increased pain. 44 
In recent years, misuse and abuse of narcotic prescriptions has risen to the forefront as an 45 
urgent and grave concern. In 2011, the Executive Office of the President of the United States 46 
identified prescription drug abuse as the nations’ fastest growing drug problem and issued a 47 
strong call for action. [13]  Surgical specialties including orthopedics, the fifth highest opioid 48 
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prescribing specialty group in the U.S. in 2012, prescribed 9.8% of all U.S. opioid prescriptions 49 
in that year.[14]  In an evaluation of half of all prescriptions issued nationwide in 2009, 50 
orthopedic surgeons prescribed 7.7% (6.1 million) of all opioid prescriptions, fourth behind 51 
primary care and internal medicine physicians and dentists.[15]  In step with many other 52 
professional organizations, the American Academy of Orthopaedic Surgeons addressed the 53 
nations’ call to action by issuing a statement on “opioid use, misuse, and abuse in orthopedics,” 54 
providing recommendations for addressing excessive and inappropriate opioid consumption in 55 
orthopedic patients. [16]   Subsequently, several studies have identified preoperative opioid use, 56 
age, and sex, among other factors, as strong predictors of continued opioid use after TKA. [17-57 
19]   In this study, we examined the effect of tourniquet use on pain and opioid consumption in 58 
the early postoperative period following TKA performed with modern perioperative pain 59 
protocols. Blood loss in tourniquet and non-tourniquet TKAs is presented as a secondary 60 
outcome. 61 
Methods 62 
Study Sample 63 
A retrospective study of 203 primary unilateral cemented TKAs consecutively performed 64 
at a single academic institution between January 2016 and March 2017 was conducted with 65 
Institutional Review Board approval. Inclusion criteria included unilateral cemented TKA 66 
secondary to primary osteoarthritis, traumatic osteoarthritis, or inflammatory arthritis.  To 67 
maintain scientific validity of the study by minimizing confounding variables, patients who took 68 
antiplatelet medications except aspirin (n = 8), had a clotting disorder (n = 6), unplanned 69 
tourniquet disruption (n = 4), or preexisting periarticular hardware (n = 1) were excluded.  The 70 
final analysis sample consisted of 184 TKAs, 93 of which included the use of a tourniquet and 91 71 
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of which did not.  The consecutive series of surgeries performed with a tourniquet was 72 
immediately followed by the consecutive series of cases performed without a tourniquet. To 73 
maximize the effect of limb ischemia time on the outcome variables, the tourniquetless knee 74 
group did not have a tourniquet inflated at any time including during cementation of 75 
components.  Carbon dioxide compression gas (CarboJet® CO2 Bone Preparation System, 76 
Kinamed Incorporated, Camarillo, CA) was used in tourniquetless knees to optimize cement 77 
penetration. 78 
Surgical Procedure 79 
Surgeries were performed by a single fellowship-trained arthroplasty surgeon.  A median 80 
parapatellar approach was used for all procedures. Standard coronal plane femoral bone cuts 81 
were made with computer-aided navigation (Stryker Navigation, Kalamazoo, MI) and tibial cuts 82 
were performed with an extramedullary cutting guide.  The same cruciate retaining knee implant 83 
was used in all cases (EMPOWR 3D Knee™, DJO Surgical, Vista, CA). Surgeries were 84 
performed with standardized light general anesthesia, low-dose intrathecal/single-shot spinal 85 
injection of 25 mcg fentanyl and 4.5 mg bupivacaine, and a periarticualar injection of 0.2% 86 
(200mg) ropivacaine, 0.5 mg epinephrine, 80 mcg clonidine and 30 mcg ketorolac to equal 101.3 87 
mL total volume immediately following component fixation.  Dosing was identical in all 88 
patients, except that ketorolac was removed for patients with renal insufficiency.  Multimodal 89 
perioperative pain protocols were used in all cases and consisted of preoperative oxycodone, 90 
Lyrica, Celebrex (or ketorolac if sulfa allergic) and oral Tylenol 24 hours prior to 91 
surgery.  Postoperative protocols were identical with the addition of oxycontin if under 70 years 92 
of age, and tramadol if 70 or older.  The same modern perioperative pain control, clinical, and 93 
rehabilitation protocols were used for all patients. 94 
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Prior to closure of the arthrotomy, a medium hemovac drain was placed in all knees and 95 
one gram of topical tranexamic acid was applied to the site.  When tourniquets were used, the 96 
tourniquet was inflated to a pressure of 250 mm Hg from surgical incision until the postoperative 97 
sterile dressing was applied.  A pad was applied between the skin and the tourniquet cuff to 98 
protect the skin. 99 
Measurements 100 
Patient sex, age in years, body mass index (BMI), American Society of Anesthesiologists 101 
Physical Status (ASA-PS) classification, procedure time in minutes, tourniquet use (yes/no), 102 
tourniquet (limb ischemia) time in minutes, hospital length of stay (LOS) in days, and 103 
preoperative presence of lumbar spine disease, fibromyalgia or systemic lupus erythematosus, 104 
depression (controlled or uncontrolled with medications), and narcotic use (none, scheduled, or 105 
pro re nata) were retrieved from the electronic medical record (EMR).  Patients reported current 106 
narcotic use to a perioperative internal medicine specialist whose practice focuses exclusively on 107 
medical assessment and optimization prior to and following total joint arthroplasty.   108 
Primary outcomes of pain and opioid consumption during the first 24 hours after surgery 109 
were retrieved from the EMR.  Patient-reported pain scores recorded by nursing staff on a 10 110 
point scale (ranging from none to severe) every four hours were averaged to derive an overall 111 
pain score during the first 24 hours following surgery.  Narcotics consumed during the first 24 112 
hours after surgery were recorded and standardized to morphine milligram equivalents using a 113 
previously published methodology. [20]  114 
Secondary outcomes related to blood loss also were retrieved from the EMR.  Blood loss 115 
was evaluated via four metrics: (1) change in preoperative to postoperative day one hemoglobin 116 
levels in g/dL, (2) calculated total blood loss in liters, (3) total hemovac drain output in 117 
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milliliters, and (4) average drain output per hour to account for the variable time drains were in 118 
situ.  The change in hemoglobin was calculated by subtracting postoperative day one hemoglobin 119 
levels from hemoglobin levels obtained at the preoperative medical clearance appointment 120 
within thirty days of the index procedure.  Total blood loss was calculated using established 121 
methodology [21] by multiplying estimated blood volume (EBV) by the change in hemoglobin 122 
divided by the average hemoglobin level.  EBV was calculated by taking into account the height, 123 
weight, and sex of the patient.  To determine the estimated blood loss assuming slow or steady 124 
blood loss with standard maintenance intravascular fluids, the change in hematocrit, or 125 
hemoglobin, over a given time interval has been found to be ideal to determine intraoperative 126 
blood loss.[21] However, the formula for intraoperative blood loss has since been modified to 127 
better serve the purpose of estimating perioperative blood loss after TKA.[22, 23]   Drain output 128 
was measured from placement until discontinuation. The use of the last recorded time point of 129 
drain output was used to standardize drain output per hour because drain output was not always 130 
recorded at the time of discontinuation on the day after surgery. Drain hours were rounded to the 131 
nearest fifteen minutes.   132 
All data points used in this study were prospectively collected and entered into the EMR 133 
by non-study clinical personnel.  Data points were extracted from the EMR without alteration or 134 
conversion.  Because tourniquet time was collected for the study, data collection was not blinded 135 
to study group.  136 
Data Analysis 137 
Minitab 17 (State College, PA) was used for statistical analysis.  Dixon’s r22 ratio was 138 
used to test continuous variables for statistical outliers. After outliers were identified and 139 
removed (total of three data points), Anderson Darling tests were used to evaluate whether 140 
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continuous variables were normally distributed.  Student’s t-test (t) and Pearson’s correlation 141 
coefficient (r) were used to compare means of normally distributed continuous variables.  Mann 142 
Whitney (W) tests and Spearman’s rank correlation (rho) were used to compare medians of non-143 
normally distributed continuous variables.  Chi-Square (X2) with Fishers p for 2 x 2 tables was 144 
used to analyze categorical variables.  An alpha level of 0.05 was used to determine statistical 145 
significance. 146 
Results 147 
The average age of patients in the tourniquet (67.7, range 33-91 years) and no tourniquet 148 
(67.0, range 47-85 years) groups was not statistically different (t = 0.58, p = 0.561).  Median 149 
BMI in kg/m2 also did not differ in the two groups (32.7 [Q1, Q3 = 28.2, 38.5] vs. 34.2 [Q1, Q3 150 
= 28.7, 39.7], respectively, W = 8618.0, p = 0.580).  There were significantly more females in 151 
the tourniquet group (55.9%) compared to the no tourniquet group (44.1%) (X2 = 5.945, p = 152 
0.019).  Consequently, outcome analyses were performed separately for females and males. 153 
Sample demographics and covariates are presented separately based on sex and 154 
tourniquet use (yes/no) in Table 1.  Preoperative depression was 1.6 times higher in female 155 
patients for whom a tourniquet was not used compared to those for whom a tourniquet was used 156 
(p = 0.047). Depression in all patients in both groups was controlled by medication.  Age, BMI, 157 
procedure time, LOS, and the prevalence of lumbar spine disease, fibromyalgia or systemic lupus 158 
erythematosus, and preoperative narcotic use did not statistically differ among females in the two 159 
groups (p ≥ 0.578).  Among male patients, mean age was higher by 4.6 years (p = 0.046) and 160 
median procedure time was 7.9 minutes shorter (p = 0.023) in the tourniquet group. None of the 161 
other demographic characteristics statistically differentiated males with and without tourniquet 162 
use (p ≥ 0.146). 163 
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Patient-reported pain and opioid consumption are provided separately for females and 164 
males and tourniquet use in Table 2.  Females who had a tourniquet reported more postoperative 165 
pain (median pain score of 2.7 vs. 1.9, p = 0.002) and greater opioid consumption (median 166 
morphine milligram equivalents of 42.8 vs. 18.8, p < 0.001) in the first 24 hours following 167 
surgery compared to females without a tourniquet.  The presence of depression did not affect 168 
median pain scores in the first 24 hours in females with a tourniquet (2.6 vs. 2.7, W = 2017.0, p 169 
= 0.245) or those without a tourniquet (1.9 vs. 1.8, W = 1013.5, p = 0.923).  Median morphine 170 
milligram equivalents consumed in the first 24 hours by females with a tourniquet (40.4 vs. 45.6, 171 
W = 1954.0, p = 0.250) and those without a tourniquet (22.8 vs. 14.3, W = 1078.0, p = 0.291) 172 
also did not differ based on the presence of depression (no vs. yes).  Time to first opioid did not 173 
differ in females with and without a tourniquet (p = 0.525).   174 
There were no differences in self-reported pain (p = 0.192), time to first opioid (p = 175 
0.119) and amount of opioids consumed (p = 0.203) among males with and without a tourniquet 176 
(Table 2).   177 
For both females and males, respectively, tourniquet use was associated with 178 
significantly lower decreases in mean delta Hgb (-2.4 vs. -3.0 g/dL, t = 4.15, p < 0.001 and -1.7 179 
vs. -2.8 g/dL, t = 3.34, p = 0.003); less mean total blood loss (-0.9 vs. -1.1 liters, t = 3.69, p < 180 
0.001 and -0.8 vs. -1.3 liters, t = 2.69, p = 0.013); mean total drain output (220 vs. 265 ml, t = 181 
2.08, p = 0.040 and 274 vs. 426 ml, t = 2.72, p = 0.009); and mean drain output per hour (13.7  182 
vs. 17.3 ml, t = 2.70, p = 0.008 and 15.9 vs. 23.4 ml, t = 2.43, p = 0.020).  183 
Discussion 184 
 Pain after primary TKA can be substantial and has been shown to increase continued 185 
opioid use and dependence in previously opioid-naïve [24]  and opioid-experienced [25, 26] 186 
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patients.  Several studies have observed that tourniquets result in greater pain in the immediate 187 
postoperative period, [7-12] with two of those studies [7, 12] showing increased analgesia 188 
consumption as a result and one showing no differences in analgesia consumption. [11]   None of 189 
these studies examined pain and analgesia consumption separately for females and males, and 190 
modern perioperative protocols including TXA were not used.  More recently, however, 191 
evidence of sex differences in knee pain both prior to [27, 28] and after TKA [29, 30] indicating 192 
greater pain in females has been reported. 193 
We observed no differences in median pain (1.9 vs. 2.3 on a 10 point scale, p = 0.192) or 194 
opioid consumption (37.1 vs. 39.9 morphine milligram equivalents, p = 0.203) during the first 24 195 
hours after TKA in male patients with and without a tourniquet, respectively.  This may be 196 
related to existing observations that male patients with symptomatic knee osteoarthritis (OA) 197 
have significantly higher thresholds for mechanically-, heat-, and cold-induced pain at the knee 198 
than females, [27] and that pain scores adjusted for covariates are significantly lower in males at 199 
all levels of OA as measured by the Kellgren and Lawrence System. [28]  In addition, consistent 200 
with our observations, men reported significantly less pain than women 24 to 36 hours and 24 to 201 
48 hours after TKA, although tourniquet use was not addressed. [29]  Unlike our findings, 202 
however, the latter study did not find a concomitant sex difference in opioid consumption. 203 
In contrast, we found that female patients with and without tourniquets reported higher 204 
median pain (2.7 vs. 1.9, p = 0.002) and opioid consumption (42.8 vs. 18.8 morphine milligram 205 
equivalents, p < 0.001) in the same period of time.  It is noteworthy that median pain scores 206 
among females with and without tourniquets were higher than median pain scores in males with 207 
and without tourniquets.  More importantly, the difference in morphine milligram equivalents 208 
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consumed by female patients with and without tourniquets is equivalent to the difference 209 
between 80 mg compared to 35 mg of hydrocodone daily.   210 
With respect to blood loss, consistent with existing literature, tourniquet use resulted in a 211 
statistically significant reduction in blood loss for both female (p ≤ 0.040) and male (p ≤ 0.020) 212 
patients, although the total blood savings of approximately 200 milliliters is of unknown clinical 213 
significance, especially in non-anemic patients. 214 
Our primary findings suggest that, barring contraindications, switching to tourniquetless TKA 215 
for females may reduce opioid analgesia in the postoperative period in this specific demographic 216 
without dramatically increasing blood loss or adding additional operative time (Table 1).  217 
Reduced opioid use in the postoperative period is likely to reduce unwanted opioid-related side 218 
effects such as constipation, potential for immunosuppression, urinary retention, sedation, and 219 
the increased medication load required to reduce these side effects [31] and may lessen the 220 
likelihood of chronic opioid dependence. [32]  In addition, undesirable consequences associated 221 
with tourniquet use including pain, parasthesias, muscle weakness and rare, but devastating 222 
vascular injury, would be eliminated. 223 
Limitations of our study include its retrospective design, the unavailability of inpatient 224 
pain scores and opioid use beyond the first 24 hours following TKA, and limited data on 225 
preoperative narcotic use.  We were unable to provide data on inpatient pain and opioid 226 
consumption beyond 24 hours because most patients were discharged on postoperative day one 227 
resulting in a small number of data points beyond 24 hours.  We were able to control for patient 228 
narcotic use immediately prior to surgery, but did not have data on long-term narcotic use or 229 
dependence.  It is a strength of our study that TKAs were performed by a single surgeon at a 230 
single academic institution using modern perioperative pain protocols. 231 
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In light of national and profession-specific calls to action to address the opioid crisis in 232 
America, avoiding tourniquet use during TKA for females may be a relatively risk-free way to 233 
decrease opioid consumption during hospitalization.  Further study is warranted to elucidate the 234 
factors accounting for different outcomes in females and males. 235 
  236 
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Table 1: Sample Demographics and Covariates 
 FEMALES MALES 
 Tourniquet No Tourniquet Statistic p Tourniquet 
No 
Tourniquet Statistic p 
N 76 60   17 31   
Mean (Range) Age in Years 66.9 (33-91) 67.2 (47-85) t = 0.20 0.844 71.3 (61-83) 66.7 (47-83) t = 2.05 0.046 
Mean (Range) BMI (kg/m2) 33.5 (20-47) 33.8 (21-48) t = 0.27 0.788 33.5 (24-45) 34.4 (23-50) t = 0.44 0.664 
Median (Q1, Q3) Female/Mean 
(Range) Male Procedure Time in 
Minutes 
74.0 (69:80) 74.5 (67:82) W = 4158.5 0.833 77.3 (61-96) 85.2 (69-106) t = 2.40 0.023 
Median (Q1, Q3) Limb Ischemia 
Time in Minutes 70.0 (65:75) 0.0 * * 70.0 (65:80) 0.0 * * 
Median (Q1, Q3) Length of Stay 
in Days 1 (1:1) 1 (1:1) W = 4044.0 0.702 1 (1:1.5) 1 (1:1) W = 733.5 0.396 
% with Lumbar Spine Disease 18.4 15.0 X2 = 0.279 0.651 41.2 22.6 X2 = 1.838 0.201 
% with Fibromyalgia or  
Systemic Lupus Erythematosus 7.9 6.7 X
2
 = 0.074 1.000 0.0 0.0 -- -- 
% with Depression 27.6 45.0 X2 = 4.429 0.047 0.0 16.1 X2 = 3.061 0.146 
% with Uncontrolled Depression 0.0  ** ** -- 0.0 ** ** 
% with Preoperative Narcotic Use         
   None 65.8 71.7 X2 = 0.647 0.724 64.7 67.7 X2 = 0.065 0.968 
   Scheduled 6.6 6.6   11.8 9.7   
   PRN 27.6 21.7   25.5 22.6   
*Could not be tested because all values were the same for the no tourniquet group 
**X2 invalid due to low cell counts 
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Table 2: Inpatient Pain and Opioid Use Outcomes 
 FEMALES MALES 
 Tourniquet No Tourniquet Statistic p Tourniquet 
No 
Tourniquet Statistic p 
PAIN          
Median (Q1, Q3) Pain in First 24 
Hours 
2.7  
(1.8, 3.6) 
1.9  
(1.1, 2.7) W = 3408.0 0.002 
1.9  
(0.8, 2.7) 
2.3  
(1.7, 3.3) W = 820.5 0.192 
OPIOID USE          
Median (Q1, Q3) Time to First 
Opioid in Minutes 
193  
(123, 323) 
183 
(106, 343) W = 3840.0 0.525 
260 (178, 
331) 
172 
(108, 268) W = 661.5 0.119 
Median (Q1, Q3) Amount of 
Opioids in First 24 Hours in 
Morphine Milligram Equivalents 
42.8 
(28.5, 64.8) 
18.8 
(11.4, 34.2) W = 2885.5 < 0.001 
37.1 
(24.2, 57.0) 
39.9 
(34.2, 68.4) W = 819.0 0.203 
 
